Minerva Neuroscie (NERV) |
|
2.83 -0.23 (-7.52%)
|
03-05 09:08 |
|
Open: |
3.03 |
Pre. Close: |
3.06 |
|
High:
|
3.09 |
Low:
|
2.76 |
|
Volume:
|
941,098 |
Market Cap:
|
121M |
|
|
|
|
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.091 - 3.112 |
3.112 - 3.129 |
|
Low:
|
2.724 - 2.742 |
2.742 - 2.757 |
|
Close:
|
2.802 - 2.833 |
2.833 - 2.858 |
|
Technical analysis |
as of: 2021-03-05 8:50:12 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.90  One year: 4.31 |
| Support: |
Support1: 2.76 Support2: 2.30 |
| Resistance: |
Resistance1: 3.34 Resistance2: 3.69 |
| Pivot: |
3.33 |
| Moving Average: |
MA(5): 3.06 MA(20): 3.36
MA(100): 3.14 MA(250): 4.44 |
| MACD: |
MACD(12,26): -0.04 Signal(9): 0.05 |
| Stochastic oscillator: |
%K(14,3): 9.67 %D(3): 11.31 |
| RSI: |
RSI(14): 34.60 |
| 52-week: |
High: 15.22 Low: 1.81 Change(%): -66.4 |
| Average Vol(K): |
3-Month: 78873 10-Days: 46253 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.NERV has closed below the lower band by 6.0%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 11.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 19 Jan 2021
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million - GlobeNewswire
Tue, 01 Dec 2020
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone - GlobeNewswire
Mon, 02 Nov 2020
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates - GlobeNewswire
Thu, 13 Aug 2020
Minerva Neurosciences to Present at JMP Securities CNS Forum - GlobeNewswire
Mon, 03 Aug 2020
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates - GlobeNewswire
Wed, 01 Jul 2020
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202) - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
43 |
| Shares Float (M) |
37 |
|
% Held by Insiders
|
3.62 |
|
% Held by Institutions
|
70.19 |
|
Shares Short (K)
|
1,900 |
|
Shares Short P. Month (K)
|
2,000 |
Stock Financials |
|
EPS
|
-0.520 |
|
EPS Est This Year
|
-0.900 |
|
EPS Est Next Year
|
-1.340 |
|
Book Value (p.s.)
|
1.360 |
|
Profit Margin
|
-50.16 |
|
Operating Margin
|
-10.25 |
|
Return on Assets (ttm)
|
-3.0 |
|
Return on Equity (ttm)
|
-36.4 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
0.965 |
|
EBITDA (p.s.)
|
-0.098 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-41 |
|
Levered Free Cash Flow (M)
|
2 |
Stock Valuations |
|
PE Ratio
|
-5.44 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.08 |
|
Price to Sales
|
2.93 |
|
Price to Cash Flow
|
-2.96 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
